PLIANT THERAPEUTICS, INC. cotiza a 0.99 USD y tiene una capitalización bursátil de $61M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.32 | $-0.35 |
| Estimado | $-0.37 | $-0.34 | $-0.36 | $-0.38 |
| Sorpresa | — | — | +11.1% | +7.9% |
| Métrica | PLRX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -82.4% | -40.4% | -42.0% |
| ROA | -66.3% | -32.0% | -34.3% |
| Current Ratio | 12.00 | 2.84 | +9.16 |
| Debt / Equity | 0.00 | 0.28 | -0.28 |